The Board currently consists of six Directors, including three executive Directors and three independent non-executive Directors.
 
Name Position
WANG QIUQIN(王秋勤) Chairman and Executive Director
HUO ZHIHONG (霍志宏) Executive Director
Chu XUEPING(褚雪平) Executive Director
Zhou Wan (周灣) Executive Director
LEUNG Chi Kin (梁志堅) Independent non-executive Director
LI Sin Ming, Ivy (李倩明) Independent non-executive Director
SY Lai Yin, Sunny (施禮賢) Independent non-executive Director

Executive Directors
Ms. Wang QiuQin (王秋勤女士) (“Ms. Wang”), is an executive Director, the Chairman of the Board and the chief executive officer of the company and a member of the Corporate Governance Committee. Ms. Wang graduated from Zhejiang University (浙江大學) majoring in Chinese language and literature in 1999 and China Medical University (中國醫科大學) majoring in pharmacy in 2016 through a distance learning program. Ms. Wang has over 12 years of experience in the pharmaceutical distribution industry in the PRC. Ms. Wang was the merchandising assistant of Zhejiang Xin Rui Pharmaceutical Co., Ltd. (浙江新銳醫藥有限公 司) (“Zhejiang Xin Rui”), a wholly-owned subsidiary of the Company, from April 2006 to April 2008 and has been the merchandising manager of Zhejiang Xin Rui since May 2008.

Mr. Huo ZhiHong (霍志宏先生) (“Mr. Huo”), is an executive Director of the Company and a member of the Corporate Governance Committee. Mr. Huo graduated from Heilongjiang Bing Qi Gong Ye Zhi Gong University (黑龍江兵器工業職工大學) majoring in mechanical engineering in 2001. Mr. Huo has over 17 years of experience in the pharmaceutical distribution industry in the PRC. Mr. Huo was the sales representative of Heilongjiang Hong Ning Pharmaceutical Co., Ltd. (黑龍江鴻寧醫藥有限公司) from 2001 to 2004, the sales supervisor of Beijing Qi Huang Pharmaceutical Co., Ltd. (北京岐黃製藥有限公司) from 2004 to 2006, the head of Commercial Department of South China District of Zhejiang Otsuka Pharmaceutical Co., Ltd. (浙江大塚製藥有限公司) from 2006 to 2008, the deputy general manager of Guangzhou Shimalong Pharmaceutical Co., Ltd. (廣州獅馬龍藥業有限公司) from 2008 to 2014, the deputy general manager of Guangzhou Kang Ying Xin Medical Equipment Co., Ltd. (廣州康瀅鑫醫療器械有限公司) from 2014 to 2017 and has been the general manager of Cheng Mai Yi Jia Technology Advisory Co., Ltd. (澄邁壹佳技術諮詢有限公司) since June 2017.

Mr. Chu Xueping (禇雪平先生) (“Mr. Chu”), is an executive Director of the Company. Mr. Chu graduated from Dalian Medical University (大連醫科大學) majoring in pharmacy in 1993. Mr. Chu has over 10 years of experience in the pharmaceutical industry in the PRC. Mr. Chu was the deputy general manager of 北京品尚品醫藥科技有限公司 (Beijing Pin Shang Pin Medicine Technology Co. Ltd., the English name is for identification purpose only) from 2011 to 2015 and the deputy president of Hainan Noken Pharmaceutical Co., Ltd. (海南諾爾康藥業有限公司) since 2016

Ms. Zhou Wan (周灣女士) (“Ms. Zhou”), is an executive Director of the Company. Ms. Zhou joined the Group’s marketing team in February 2012 and has been promoted to the position of the general manager and legal representative of Zhejiang Xin Rui Pharmaceutical Co., Ltd. (浙江新銳醫藥有限公司), a wholly-owned subsidiary of the Company, since April 2018. Ms. Zhou graduated from Zhejiang Chinese Medical University (浙江中醫藥大學) majoring in traditional Chinese pharmacy in 2017. Ms. Zhou has more than 10 years of experience in the pharmaceutical distribution industry in the PRC.

Independent non-executive Directors
Mr. Leung Chi Kin (梁志堅先生) (“Mr. Leung”), is an independent non-executive Director of our Company. Mr. Leung was an elected member of the Shatin District Council in Hong Kong from 1994 to 2011. Mr. Leung was also awarded a Medal of Honour by the Government of Hong Kong. Mr. Leung was an independent non-executive director of each of Hanergy Thin Film Power Group Limited (formerly known as Hanergy Solar Group Limited and Apollo Solar Energy Technology Holdings Limited) (stock code: 566) (during the period from 1 May 2008 to 25 November 2009) and Silk Road Energy Services Group Limited (formerly known as China Natural Investment Company Limited) (stock code: 8250) (during the period from 27 November 2009 to 26 November 2012), the issued shares of which are listed on the Main Board of the Stock Exchange and Growth Enterprise Market, respectively.

Ms. Li Sin Ming, Ivy (李倩明女士)(“Ms. Li”), is an independent non-executive Director of our Company. Ms. Li holds a Bachelor degree of Business Administration (Honours) in Accounting from the Hong Kong Baptist University. Ms. Li is a Certified Public Accountant of the Hong Kong Institute of Certified Public Accountants and a fellow of the Association of Chartered Certified Accountants. Ms. Li has about 20 years of accounting and auditing experience. Ms. Li worked in various audit firms and the finance department of several companies.

Mr. Sy Lai Yin, Sunny (施禮賢先生) (“Mr. Sy”), is an independent non-executive Director of our Company. Mr. Sy graduated from Washington University with a Bachelor’s Degree of Science in Business Administration. He was awarded a degree of Master of Science in Business Administration by Washington University in December 2001. Mr. Sy has over five years of experience in accounting and auditing with an international accountancy and professional services firm. Mr. Sy has also been a director of Bradbury Securities Limited, a corporation licensed to carry on Type 1 (dealing in securities) and Type 4 (advising on securities) regulated activities under the Securities and Futures Ordinance (Chapter 571, the Laws of Hong Kong) since 2008.